Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.92 USD
+0.16 (5.80%)
Updated May 1, 2024 04:00 PM ET
After-Market: $2.91 -0.01 (-0.34%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALLO 2.92 +0.16(5.80%)
Will ALLO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ALLO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALLO
Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
ALLO: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Allogene (ALLO) Stock Stands Out in a Strong Industry
Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss
Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates
Other News for ALLO
Amgen’s Blincyto data send Cullinan higher
Commit To Purchase Allogene Therapeutics At $2.50, Earn 32.6% Annualized Using Options
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Allogene awarded $15M grant from CIRM to support ALLO-316 development
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation